Natixis Acquires Shares of 5,131 DaVita Inc. (NYSE:DVA)

Natixis bought a new stake in DaVita Inc. (NYSE:DVA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,131 shares of the company’s stock, valued at approximately $708,000.

Several other institutional investors and hedge funds also recently made changes to their positions in DVA. Pitcairn Co. bought a new stake in DaVita in the first quarter valued at about $264,000. CANADA LIFE ASSURANCE Co lifted its stake in DaVita by 31.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 63,066 shares of the company’s stock worth $8,709,000 after purchasing an additional 15,189 shares during the last quarter. Bessemer Group Inc. boosted its holdings in DaVita by 2,335.6% in the first quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after purchasing an additional 10,300 shares during the period. UniSuper Management Pty Ltd increased its stake in DaVita by 619.4% during the first quarter. UniSuper Management Pty Ltd now owns 7,323 shares of the company’s stock valued at $1,011,000 after purchasing an additional 6,305 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its holdings in shares of DaVita by 13.7% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 20,890 shares of the company’s stock valued at $2,884,000 after buying an additional 2,512 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of NYSE DVA traded down $2.29 during mid-day trading on Friday, reaching $140.21. The company had a trading volume of 159,179 shares, compared to its average volume of 835,664. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $147.93. The stock has a market cap of $12.30 billion, a PE ratio of 16.19, a P/E/G ratio of 1.10 and a beta of 0.87. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The company has a 50-day moving average price of $140.68 and a two-hundred day moving average price of $131.01.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. The business had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. DaVita’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 EPS. On average, equities analysts anticipate that DaVita Inc. will post 9.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Barclays raised their target price on shares of DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. TD Cowen upped their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday. Finally, Truist Financial boosted their target price on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $146.00.

Insider Transactions at DaVita

In related news, Director Barbara J. Desoer sold 5,030 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the sale, the director now owns 10,954 shares of the company’s stock, valued at approximately $1,520,524.74. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.